Oppenheimer & Co’s ImmunityBio IBRX Stock Holding History

Oppenheimer & Co’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,720	Closed	-$143K	–	1523
2021 Q3	$143K	Buy	+14,720	New	+$162K	﹤0.01%	1429
2020 Q1	–	Sell	-15,600	Closed	-$59K	–	1255
2019 Q4	$59K	Sell	15,600 -17,000	-52%	-$28.9K	﹤0.01%	1252
2019 Q3	$40K	Hold	32,600	–	–	﹤0.01%	1237
2019 Q2	$33K	Hold	32,600	–	–	﹤0.01%	1286
2019 Q1	$52K	Hold	32,600	–	–	﹤0.01%	1325
2018 Q4	$38K	Sell	32,600 -2,000	-6%	-$4.58K	﹤0.01%	1217
2018 Q3	$128K	Buy	34,600 +17,800	+106%	+$56.3K	﹤0.01%	1293
2018 Q2	$51K	Buy	16,800 +6,500	+63%	+$24.1K	﹤0.01%	1304
2018 Q1	$40K	Hold	10,300	–	–	﹤0.01%	1314
2017 Q4	$46K	Buy	+10,300	New	+$48.8K	﹤0.01%	1293
2017 Q2	–	Sell	-11,100	Closed	-$39K	–	1325
2017 Q1	$39K	Buy	+11,100	New	+$54.8K	﹤0.01%	1262
2016 Q3	–	Sell	-10,100	Closed	-$63K	–	1287
2016 Q2	$63K	Buy	+10,100	New	+$78.4K	﹤0.01%	1187

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Oppenheimer & Co's IBRX Position: Q4 2021 in Review

Oppenheimer & Co sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 14,720 shares — an estimated $143K sold.

Oppenheimer & Co first reported a position in IBRX in Q2 2016 and held it in 12 quarters. The position peaked at $143K in Q3 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

Oppenheimer & Co reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
Oppenheimer & Co sold 14,720 ImmunityBio shares in Q4 2021, an estimated $143K.
Oppenheimer & Co first reported a position in ImmunityBio in Q2 2016 and held it in 12 quarters.
Oppenheimer & Co's ImmunityBio position peaked at $143K in Q3 2021.
141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.